Research ExplorerPublicationsGuidelines on testicular cancer

Guidelines on testicular cancer

Standard

Guidelines on testicular cancer. / Albers, Peter; Albrecht, Walter; Algaba, Ferran; Bokemeyer, Carsten; Cohn-Cedermark, Gabriella; Horwich, Alan; Klepp, Olbjoern; Laguna, M Pilar; Pizzocaro, Giorgio.

In: EUR UROL, Vol. 48, No. 6, 12.2005, p. 885-94.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Albers, P, Albrecht, W, Algaba, F, Bokemeyer, C, Cohn-Cedermark, G, Horwich, A, Klepp, O, Laguna, MP & Pizzocaro, G 2005, 'Guidelines on testicular cancer', EUR UROL, vol. 48, no. 6, pp. 885-94. https://doi.org/10.1016/j.eururo.2005.06.019

APA

Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Horwich, A., Klepp, O., Laguna, M. P., & Pizzocaro, G. (2005). Guidelines on testicular cancer. EUR UROL, 48(6), 885-94. https://doi.org/10.1016/j.eururo.2005.06.019

Vancouver

Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Horwich A et al. Guidelines on testicular cancer. EUR UROL. 2005 Dec;48(6):885-94. https://doi.org/10.1016/j.eururo.2005.06.019

Bibtex

@article{0070217021a141128f0cae69171bdac4,
title = "Guidelines on testicular cancer",
abstract = "OBJECTIVE: To up-date the 2001 version of the EAU testicular cancer guidelines.METHODS: A non-structured literature review until January 2005 using the MEDLINE database has been performed. Literature has been classified according to evidence-based medicine levels.RESULTS: Testicular cancer is a highly curable disease. Excellent cure rates have been achieved by standardization of treatment, interdisciplinary management, and tremendous success in performing clinical trials. Currently, the aims of testicular cancer treatment are as follows: for patients with low-stage disease, a reduction in treatment is proposed to improve long-term toxicity in these patients with unaltered life expectancy; for about 10% of patients with advanced disease and poor prognosis, intensification of treatment (including high-dose chemotherapy and new drugs as well as aggressive surgical approaches) is being investigated to improve long-term cure rates.CONCLUSION: Guidelines will improve clinical practice only if they are regularly updated. This update presents the state-of-the-art management of testicular cancer patients in 2005.",
keywords = "Adult, Chemotherapy, Adjuvant, Combined Modality Therapy, Humans, Male, Middle Aged, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal, Practice Guidelines as Topic, Prognosis, Radiotherapy, Adjuvant, Risk Assessment, Survival Rate, Testicular Neoplasms, Treatment Outcome, Urologic Surgical Procedures, Male",
author = "Peter Albers and Walter Albrecht and Ferran Algaba and Carsten Bokemeyer and Gabriella Cohn-Cedermark and Alan Horwich and Olbjoern Klepp and Laguna, {M Pilar} and Giorgio Pizzocaro",
year = "2005",
month = dec,
doi = "10.1016/j.eururo.2005.06.019",
language = "English",
volume = "48",
pages = "885--94",
journal = "EUR UROL",
issn = "0302-2838",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Guidelines on testicular cancer

AU - Albers, Peter

AU - Albrecht, Walter

AU - Algaba, Ferran

AU - Bokemeyer, Carsten

AU - Cohn-Cedermark, Gabriella

AU - Horwich, Alan

AU - Klepp, Olbjoern

AU - Laguna, M Pilar

AU - Pizzocaro, Giorgio

PY - 2005/12

Y1 - 2005/12

N2 - OBJECTIVE: To up-date the 2001 version of the EAU testicular cancer guidelines.METHODS: A non-structured literature review until January 2005 using the MEDLINE database has been performed. Literature has been classified according to evidence-based medicine levels.RESULTS: Testicular cancer is a highly curable disease. Excellent cure rates have been achieved by standardization of treatment, interdisciplinary management, and tremendous success in performing clinical trials. Currently, the aims of testicular cancer treatment are as follows: for patients with low-stage disease, a reduction in treatment is proposed to improve long-term toxicity in these patients with unaltered life expectancy; for about 10% of patients with advanced disease and poor prognosis, intensification of treatment (including high-dose chemotherapy and new drugs as well as aggressive surgical approaches) is being investigated to improve long-term cure rates.CONCLUSION: Guidelines will improve clinical practice only if they are regularly updated. This update presents the state-of-the-art management of testicular cancer patients in 2005.

AB - OBJECTIVE: To up-date the 2001 version of the EAU testicular cancer guidelines.METHODS: A non-structured literature review until January 2005 using the MEDLINE database has been performed. Literature has been classified according to evidence-based medicine levels.RESULTS: Testicular cancer is a highly curable disease. Excellent cure rates have been achieved by standardization of treatment, interdisciplinary management, and tremendous success in performing clinical trials. Currently, the aims of testicular cancer treatment are as follows: for patients with low-stage disease, a reduction in treatment is proposed to improve long-term toxicity in these patients with unaltered life expectancy; for about 10% of patients with advanced disease and poor prognosis, intensification of treatment (including high-dose chemotherapy and new drugs as well as aggressive surgical approaches) is being investigated to improve long-term cure rates.CONCLUSION: Guidelines will improve clinical practice only if they are regularly updated. This update presents the state-of-the-art management of testicular cancer patients in 2005.

KW - Adult

KW - Chemotherapy, Adjuvant

KW - Combined Modality Therapy

KW - Humans

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Neoplasms, Germ Cell and Embryonal

KW - Practice Guidelines as Topic

KW - Prognosis

KW - Radiotherapy, Adjuvant

KW - Risk Assessment

KW - Survival Rate

KW - Testicular Neoplasms

KW - Treatment Outcome

KW - Urologic Surgical Procedures, Male

U2 - 10.1016/j.eururo.2005.06.019

DO - 10.1016/j.eururo.2005.06.019

M3 - SCORING: Journal article

C2 - 16126333

VL - 48

SP - 885

EP - 894

JO - EUR UROL

JF - EUR UROL

SN - 0302-2838

IS - 6

ER -